Journal of General Internal Medicine

, Volume 22, Issue 8, pp 1166–1171

NSAIDs and Colorectal Cancer Risk: Do Administrative Data Support a Chemopreventive Effect?

  • Elizabeth B. Lamont
  • Lauren E. Dias
  • Diane S. Lauderdale
Original Article



Randomized trials show non-steroidal anti-inflammatory drugs (NSAIDs) reduce precancerous polyps. Observational studies of the NSAID aspirin (ASA) suggest that it reduces invasive colorectal cancer (CRC) incidence, but because ASA use may also be a marker for healthy behaviors, these studies may be subject to selection bias. We sought to estimate the effectiveness of NSAIDs in CRC prevention in the population of elderly Medicare beneficiaries, minimizing this selection bias.


With National Ambulatory Medical Care Survey data, we find that patients with a diagnosis of osteoarthritis (OA) are 4.4 times more likely to concurrently have NSAID use documented than patients without such a diagnosis. We use this figure to estimate the expected NSAID-mediated reduction in CRC risk associated with a diagnosis of OA. Using Survival Epidemiology and End-Results (SEER)-Medicare data, we compare cases of elderly Medicare beneficiaries diagnosed with CRC in 1995 to persons without CRC to determine if their odds of antecedent OA differ.


We estimate the expected NSAID-mediated reduction in CRC associated with an OA diagnosis to be between 6 and 16% (i.e., RR, 0.84–0.94). In the SEER-Medicare data, we find that individuals with a diagnosis of OA in Medicare claims in the previous 3 years had 15% lower odds of being diagnosed with CRC than individuals whose claims did not reflect antecedent OA (OR 0.85, 95%CI 0.80–0.91).


This case-control study finds that elderly Medicare beneficiaries with histories of OA have 15% lower odds of developing CRC. These results are consistent with a preventive role for NSAIDs in CRC among the elderly.


colorectal cancer prevention aging 


  1. 1.
    Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005;55(1):10–30.PubMedGoogle Scholar
  2. 2.
    Janne P, Mayer R. Chemoprevention of colorectal cancer. N Engl J Med. 2000;342:1960–8.PubMedCrossRefGoogle Scholar
  3. 3.
    Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology. 1994;107:1183–8.PubMedGoogle Scholar
  4. 4.
    Fujita T, Matsui M, Takaku K, et al. Size- and invasion-dependent increase in cyclooxygenase 2 levels in human colorectal carcinomas. Cancer Res. 1998;58:4823–6.PubMedGoogle Scholar
  5. 5.
    Labayle D, Fischer D, Vielh P, et al. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology. 1991;101(3):635–9 (Sep).PubMedGoogle Scholar
  6. 6.
    Nugent KP, Farmer KC, Spigelman AD, Williams CB, Phillips RK. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br J Surg. 1993;80(12):1618–9 (Dec).PubMedCrossRefGoogle Scholar
  7. 7.
    Giardiello FM, Hamilton SR, Krush AJ, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med. 1993;328(18):1313–6.PubMedCrossRefGoogle Scholar
  8. 8.
    Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med. 2000;342(26):1946–52.PubMedCrossRefGoogle Scholar
  9. 9.
    Sandler RS, Halabi S, Baron JA, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med. 2003;348:883–90.PubMedCrossRefGoogle Scholar
  10. 10.
    Baron JA, Cole BF, Sandler RS, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med. 2003;348:891–9.PubMedCrossRefGoogle Scholar
  11. 11.
    Chan AT, Giovannucci EL, Schernhammer ES, et al. A prospective study of aspirin use and the risk for colorectal adenoma. Ann Intern Med. 2004;140:157–66.PubMedGoogle Scholar
  12. 12.
    Rosenberg L, Palmer JR, Zauber AG, Warshauer ME, Stolley PD, Shapiro S. A hypothesis: nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer. J Natl Cancer Inst. 1991;83:355–8.PubMedCrossRefGoogle Scholar
  13. 13.
    Sansbury LB, Millikan RC, Schroeder JC, Moorman PG, North KE, Sandler RS. Use of nonsteroidal antiinflammatory drugs and risk of colon cancer in a population-based, case-control study of African Americans and Whites. Am J Epidemiol. 2005;162(6):548–58.PubMedCrossRefGoogle Scholar
  14. 14.
    Thun MJ, Namboodiri MM, Heath CW Jr. Aspirin use and reduced risk of fatal common cancer. N Engl J Med. 1991;325:1593–6.PubMedCrossRefGoogle Scholar
  15. 15.
    Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, Willett WC. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med. 1994;121(4):241–6.PubMedGoogle Scholar
  16. 16.
    Giovannucci E, Egan KM, Hunter DJ, et al. Aspirin and the risk of colorectal cancer in women. N Engl J Med. 1995;333(10):609–14.PubMedCrossRefGoogle Scholar
  17. 17.
    Chan AT, Giovannucci EL, Meyerhardt JA, Schernhammer ES, Curhan GC, Fuchs CS. Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA. 2005;294(8):914–23.PubMedCrossRefGoogle Scholar
  18. 18.
    Sturmer T, Glynn RJ, Lee I-M, Manson JE, Buring JE, Hennekens CH. Aspirin use and colorectal cancer: post-trial follow-up data from the Physicians’ Health Study. Ann Intern Med. 1998;128:713–20.PubMedGoogle Scholar
  19. 19.
    Cook NR, Lee IM, Gaziano JM, et al. Low-dose aspirin in the primary prevention of cancer: the Women’s Health Study: a randomized controlled trial. JAMA. 2005;294(1):47–55.PubMedCrossRefGoogle Scholar
  20. 20.
    Sturmer T, Buring JE, Lee IM, Kurth T, Gaziano JM, Glynn RJ. Colorectal cancer after start of non-steroidal anti-inflammatory drug use. Am J Med. 2006;119(6):494–502.PubMedCrossRefGoogle Scholar
  21. 21.
    National Center for Health Statistics. NAMCS description. Available at: Accessed January 22, 2007.
  22. 22.
    National Center for Health Statistics. NAMCS data collection and processing. Accessed April 4, 2007.
  23. 23.
    National Cancer Institute. SEER-Medicare linked database. Available at: Accessed January 22, 2007.
  24. 24.
    National Cancer Institute. SEER: surveillance epidemiology and end results. Available at: Accessed January 22, 2007.
  25. 25.
    Hatten J. Medicare’s common denominator: the covered population. Health Care Financ Rev. 1980;53–64.Google Scholar
  26. 26.
    Katz JN, Barrett J, Liang MH, et al. Sensitivity and positive predictive value of Medicare part B physician claims for rheumatologic diagnoses and procedures. Arthritis Rheum. 1997;40(9):1594–600.PubMedCrossRefGoogle Scholar
  27. 27.
    Mahomed NN, Barrett J, Katz JN, Baron JA, Wright J, Losina E. Epidemiology of total knee replacement in the United Sates Medicare population. J Bone Jt Surg. 2005;87A(6):1222–8.CrossRefGoogle Scholar
  28. 28.
    Quam JP, Michet CJ, Wilson MG, et al. Total knee arthroplasty: a population-based study. Mayo Clin Proc. 1991;66(6):589–95.PubMedGoogle Scholar
  29. 29.
    Baron JA, Cole BF, Sandler RS, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med. 2003;348:891–899.CrossRefGoogle Scholar
  30. 30.
    Giardiello FM, Hamilton SR, Krush AJ, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med. 1993;328(18):1313–6.PubMedCrossRefGoogle Scholar
  31. 31.
    U.S. Preventive Services Task Force. Aspirin or nonsteroidal anti-inflammatory drugs for the primary prevention of colorectal cancer. Accessed April 4, 2007.
  32. 32.
    McCashland TM, Brand R, Lyden E, de Garmo P. Gender differences in colorectal polyps and tumors. Am J Gastroenterol. 2001;96:882–6.PubMedCrossRefGoogle Scholar
  33. 33.
    Troisi RJ, Freedman AN, Devesa SS. Incidence of colorectal carcinoma in the U.S. Cancer. 1999;85:1670–6.PubMedCrossRefGoogle Scholar
  34. 34.
    Anderson WF, Umar A, Brawley OW. Colorectal carcinoma in black and white race. Cancer Metastasis Rev. 2003;22:67–82.PubMedCrossRefGoogle Scholar
  35. 35.
    Parker SL, Davis KJ, Wingo PA, Ries LA, Heath CW Jr. Cancer statistics by race and ethnicity. CA Cancer J Clin. 1998;48:31–48.PubMedCrossRefGoogle Scholar
  36. 36.
    Lauderdale DS, Goldberg J. The expanded racial and ethnic codes in the Medicare data files: their completeness of coverage and accuracy. Am J Public Health. 1996;86(5):712–6.PubMedGoogle Scholar
  37. 37.
    Fisher ES, Baron JA, Malenka DJ, Barrett J, Bubolz TA. Overcoming potential pitfalls in the use of Medicare data for epidemiologic research. Am J Public Health. 1990;80:1487–90.PubMedCrossRefGoogle Scholar
  38. 38.
    Mitchell JB, Bubolz T, Paul JE, et al. Using Medicare claims for outcomes research. Med Care. 1994;32:JS38–51.PubMedCrossRefGoogle Scholar
  39. 39.
    Lauderdale D, Furner SE, Miles TP, Goldberg J. Epidemiological uses of Medicare data. Epidemiol Rev. 1993;15(2):319–27.PubMedGoogle Scholar
  40. 40.
    Cooley HM, Stankocich J, Jones G. The association between hormonal and reproductive factors and hand osteoarthritis. Maturitas. 2003;45(4):257–65.PubMedCrossRefGoogle Scholar
  41. 41.
    Amin S, Niu J, Guermazi A, et al. Cigarette smoking and the risk for cartilage loss and knee pain in men with knee osteoarthritis. Ann Rheum Dis. 2007;66(1):18–22.PubMedCrossRefGoogle Scholar
  42. 42.
    Ding C, Cicuttini F, Scott F, et al. Natural history of knee cartilage defects and factors affecting change. Arch Intern Med. 2006;166(6):651–8.PubMedCrossRefGoogle Scholar
  43. 43.
    Hirata S, Ono R, Yamada M, et al. Ambulatory physical activity, disease severity, and employment status in adult women with osteoarthritis of the hip. J Rheumatol. 2006;33(5):939–45.PubMedGoogle Scholar

Copyright information

© Society of General Internal Medicine 2007

Authors and Affiliations

  • Elizabeth B. Lamont
    • 1
    • 2
  • Lauren E. Dias
    • 1
    • 3
  • Diane S. Lauderdale
    • 4
  1. 1.Massachusetts General Hospital Cancer CenterBostonUSA
  2. 2.Departments of Medicine and Health Care PolicyHarvard Medical SchoolBostonUSA
  3. 3.North Shore Medical CenterPeabodyUSA
  4. 4.Department of Health StudiesUniversity of ChicagoChicagoUSA

Personalised recommendations